AZ laser-focused on 1M target

Ensuring chronic kidney disease (CKD) patients have earlier and faster access to treatments is at the top of AstraZeneca’s priority list with the company’s Business Unit Director for Cardiovascular Renal and Metabolism, Cecelia Bagley, spearheading the push for policy reform in Australia.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here